Niagen Bioscience (NAGE) Common Equity (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Common Equity of $82.3 million for Q1 2026, up 48.76% year-over-year from $55.3 million in Q1 2025, and up 7.57% quarter-over-quarter from $76.5 million in Q4 2025.
Niagen Bioscience (NAGE) Common Equity (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Common Equity for 15 consecutive years, with $82.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 48.76% year-over-year to $82.3 million; the TTM figure through Mar 2026 stood at $82.3 million (up 48.76% YoY), while the FY2025 annual figure was $76.5 million, up 66.04% from the prior year.
- Common Equity climbed to $82.3 million in Q1 2026 per NAGE's latest filing, from $76.5 million in the prior quarter.
- Across five years, Common Equity topped out at $82.3 million in Q1 2026 and bottomed at $20.8 million in Q2 2022.
- Historically, Common Equity has averaged $41.0 million across 5 years, with a median of $29.0 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity slumped 50.7% — and 2025, when it jumped 108.98%.
- Niagen Bioscience's Common Equity stood at $28.7 million in 2022, then declined by 0.75% to $28.5 million in 2023, then surged by 61.98% to $46.1 million in 2024, then surged by 66.04% to $76.5 million in 2025, then climbed by 7.57% to $82.3 million in 2026.
- Business Quant data shows NAGE's Common Equity at $82.3 million in Q1 2026, $76.5 million in Q4 2025, and $70.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 82.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 82.53 Mn |
| Mar 31, 2026 | 82.33 Mn |
| Dec 31, 2025 | 76.53 Mn |
| Sep 30, 2025 | 70.68 Mn |
| Jun 30, 2025 | 64.20 Mn |
| Mar 31, 2025 | 55.35 Mn |
| Dec 31, 2024 | 46.09 Mn |
| Sep 30, 2024 | 34.37 Mn |
| Jun 30, 2024 | 30.72 Mn |
| Mar 31, 2024 | 28.95 Mn |
| Dec 31, 2023 | 28.46 Mn |
| Sep 30, 2023 | 27.31 Mn |
| Jun 30, 2023 | 27.15 Mn |
| Mar 31, 2023 | 28.02 Mn |
| Dec 31, 2022 | 28.67 Mn |
| Sep 30, 2022 | 21.02 Mn |
| Jun 30, 2022 | 20.78 Mn |
| Mar 31, 2022 | 25.88 Mn |
| Dec 31, 2021 | 31.73 Mn |
| Sep 30, 2021 | 35.45 Mn |